Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Biggest benefit to manufacturers from the insurer's upcoming program may be relieving public pressure on list prices.
Latest From Pricing Debate
The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.
HHS secretary urges serious proposals from biopharma on enhancing price negotiation in Medicare Parts D and B, promising action from the Administration whether the industry cooperates or not.
President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.
Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.
Advances in psoriasis therapy in the last few years have revolutionized the treatment of the condition and a high percentage of patients are achieving clear or nearly clear skin, thanks to drugs targeting interleukin-17, 12 and 23. What's more, a number of payers are increasingly recognizing these new treatments as cost-effective. Scrip's infographic provides a snapshot.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.